Brain HealthLandmark Trial Tested Donepezil and Vitamin E to Delay Alzheimer's Disease
The Memory Impairment Study investigated whether donepezil or vitamin E could delay progression from mild cognitive impairment to Alzheimer's disease. Mild cognitive impairment involves memory problems beyond normal aging without dementia, making it an important target for preserving independence. Sponsored by the National Institute on Aging, this phase 3 trial began in March 1999 and was completed in January 2004. The supplied description proposed 65 to 80 research sites in the United States and Canada and compared the treatments with placebo. However, the abstract provides no trial results, participant counts, doses, or safety findings. Its reference to a seven-month delay in dementia milestones comes from a separate 1997 vitamin E study, not this trial. This abstract alone cannot establish that either treatment prevents Alzheimer's disease or justify starting treatment.